ArriVent BioPharma Analyst Price Targets - Benzinga

SPY778.570.00%QQQ751.38+0.01%BTC/USD82,572.19+0.01%DIA516.21+0.02%GLD384.50−0.02%TLT77.97−0.02%

ArriVent BioPharma Inc

AVBPNASDAQ

Trade with Public

Trade with Public

$16.73

0.020.12%

Last update: Oct 9, 7:46 PM

$16.57

-0.14-0.84%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

ArriVent BioPharma Analyst Price Targets - Benzinga

ArriVent BioPharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for ArriVent BioPharma (AVBP).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

12Buy

Consensus RatingBuy# Analysts12Avg. Consensus PT$33Upside to Avg. PT+99.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$47→$27
Oct 7, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$40→$20
Oct 7, 2026	Jones Trading	Soumit Roy	PT Cut	Buy	$45→$22
Oct 7, 2026	Truist Securities	Supawat Thongthip	PT Cut	Buy	$45→$18
Oct 7, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$45→$18
Oct 7, 2026	BTIG	Jeet Mukherjee	PT Cut	Buy	$42→$29
Aug 17, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$44→$47
Aug 13, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$43→$40
Aug 13, 2026	Guggenheim	Michael Schmitz	Maintained	Buy	$45
Aug 13, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$42
May 29, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$43→$45
May 13, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$45→$43
Apr 24, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$33→$45
Mar 23, 2026	B. Riley Securities	Kalpit Patel	PT Raise	Buy	$37→$45
Mar 12, 2026	BTIG	Jeet Mukherjee	Assumes	Buy	$42
Mar 6, 2026	Oppenheimer	Jeff Jones	PT Raise	Outperform	$44→$50
Mar 6, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$31→$33
Mar 6, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$42→$44
Dec 23, 2025	Cantor Fitzgerald	Li Watsek	Initiate	Overweight	—
Dec 10, 2025	BTIG	Justin Zelin	Initiate	Buy	$45

More with Benzinga EdgeGet Access

Analyst Ratings News

Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday

Analysts raised targets for Everpure, Eli Lilly and Delek US, while cutting targets for Constellation, Tyler, ArriVent and Netflix.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Lowers Price Target to $27

HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $47 to $27.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $20

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $40 to $20.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18

Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $18.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18

Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $18.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29

BTIG analyst Jeet Mukherjee maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $42 to $29.

Benzinga Newsdesk